Mycenax Biotech Inc. (TPEX:4726)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
37.50
+0.20 (0.54%)
Apr 2, 2025, 1:30 PM CST
-2.72%
Market Cap 7.52B
Revenue (ttm) 683.92M
Net Income (ttm) -467.13M
Shares Out 207.01M
EPS (ttm) -2.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 128,684
Average Volume 250,974
Open 37.30
Previous Close 37.30
Day's Range 36.90 - 37.65
52-Week Range 36.35 - 65.20
Beta 1.09
RSI 20.78
Earnings Date Mar 14, 2025

About Mycenax Biotech

Mycenax Biotech Inc., a contract development and manufacturing organization company, provides biopharmaceutical services and solutions for drug development and production in Taiwan, Japan, Korea, Singapore, rest of the Asia-Pacific regions, Europe, and the United States. The company’s services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers plasmid DNA, antibody-dru... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 387
Stock Exchange Taipei Exchange
Ticker Symbol 4726
Full Company Profile

Financial Performance

In 2024, Mycenax Biotech's revenue was 683.92 million, an increase of 4.80% compared to the previous year's 652.62 million. Losses were -467.13 million, -31.59% less than in 2023.

Financial Statements

News

There is no news available yet.